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OBJECTIVE—The aim of the study is to evaluate the effect of
nanoparticle-mediated gene delivery of angiogenic inhibitors on
retinal inﬂammation, vascular leakage, and neovascularization in
diabetic retinopathy.
RESEARCH DESIGN AND METHODS—An expression plas-
mid of plasminogen kringle 5 (K5), a natural angiogenic inhibitor,
was encapsulated with poly(lactide-coglycolide) to form K5
nanoparticles (K5-NP). Expression of K5 was determined by
Western blot analysis and immunohistochemistry, and retinal
vascular leakage was measured by permeability assay. Retinal
neovascularization was evaluated using ﬂuorescein-angiography
and counting preretinal vascular cells in rats with oxygen-
induced retinopathy. Effects of K5-NP on retinal inﬂammation
were evaluated in streptozotocin-induced diabetic rats by leuko-
stasis assay and Western blot analysis of intracellular adhesion
molecule and vascular endothelial growth factor. Possible toxic-
ities of K5-NP were evaluated using histology examination,
retinal thickness measurement, and electroretinogram recording.
RESULTS—K5-NP mediated efﬁcient expression of K5 and
speciﬁcally inhibited growth of endothelial cells. An intravitreal
injection of K5-NP resulted in high-level expression of K5 in the
inner retina of rats during the 4 weeks they were analyzed.
Injection of K5-NP signiﬁcantly reduced retinal vascular leakage
and attenuated retinal neovascularization, when compared with
the contralateral eyes injected with Control-NP in oxygen-in-
duced retinopathy rats. K5-NP attenuated vascular endothelial
growth factor and intracellular adhesion molecule-1 overexpres-
sion and reduced leukostasis and vascular leakage for at least 4
weeks after a single injection in the retina of streptozotocin-
induced diabetic rats. No toxicities of K5-NP were detected to
retinal structure and function.
CONCLUSIONS—K5-NP mediates efﬁcient and sustained K5
expression in the retina and has therapeutic potential for diabetic
retinopathy. Diabetes 58:1902–1913, 2009
R
etinal vascular leakage and neovascularization
are the major features of diabetic retinopathy
and the leading causes of vision loss (1–3).
These retinal vascular abnormalities are also
common in other ocular disorders such as sickle cell
retinopathy, retinal vein occlusion, and retinopathy of
prematurity (1,4,5). Vascular endothelial growth factor
(VEGF) plays a key pathogenic role in the blood-retinal
barrier breakdown or vascular leakage and retinal neovas-
cularization (6–8).
Angiogenesis is regulated by two counter-balancing
systems between angiogenic stimulators, such as VEGFs
and angiogenic inhibitors such as angiostatin (4,9,10).
Angiostatin contains the ﬁrst four triple disulﬁde bond-
linked loops of plasminogen known as kringle domains
and is a potent inhibitor of angiogenesis (11). Among
proteolytic fragments of plasminogen, kringle 5 (K5), an
80–amino acid peptide from plasminogen, has the most
potent inhibitory effect on endothelial cell growth (12).
Previously, we have shown that K5 inhibits ischemia-
induced retinal neovascularization in the oxygen-induced
retinopathy (OIR) model (13). K5 also reduces retinal
vascular leakage in the OIR model and in the streptozoto-
cin (STZ)-induced diabetes model (14). The K5-induced
reduction of vascular leakage is achieved through an
intraocular, periocular, topical, or systemic administration
of the K5 peptide (15). Similar to that of many other
anti-angiogenic peptides, however, these K5 effects are
transient after a single injection of the K5 peptide because
of its short half-life in the retina (14,15). A sustained ocular
delivery of K5, such as gene therapy, is desirable for
the development of a long-term treatment of diabetic
retinopathy.
Traditionally, gene delivery systems can be classiﬁed
into viral vector-mediated and nonviral deliveries. Cur-
rently, viral vectors are the most commonly used means
for gene delivery because of their high efﬁciencies (16,17).
The limitations of viral vector-mediated delivery, such as
potential risks, restricted targeting of speciﬁc cell types,
and immunogenecity of viral vectors hamper their clinical
application (18,19). For these reasons, nonviral systems
for gene delivery have become increasingly desirable in
both basic research and clinical settings.
One of the emerging nonviral vector-mediated gene
delivery systems is condensation of plasmid DNA or
oligonucleotides into nanoparticles (20). There are several
biocompatible polymers to be used for DNA delivery, such
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1902 DIABETES, VOL. 58, AUGUST 2009as poly(D,L-lactide-coglycolide) (PLGA) and poly(ethylene-
covinyl acetate) (EVAc). Several groups have successfully
encapsulated naked DNA into biodegradable PLGA nano-
particles for long-term and controlled DNA release (21).
Although matrix-type nanoparticles have been formulated
using different polymers, the nanoparticles formulated
from PLGA are especially of interest for gene delivery
because of their safety, biocompatibility, biodegradability,
and sustained release characteristics (22,23).
We encapsulated an expression plasmid of K5 with
PLGA polymer to form nanoparticles and evaluated the
efﬁcacy of these K5 nanoparticles (K5-NP) on ischemia-
induced retinal vascular leakage and retinal neovascular-
ization in the OIR rat model. We evaluated the effects of
K5-NP on retinal inﬂammation in STZ-induced diabetic
rats. In addition, we also tested the ocular toxicities of
K5-NP.
RESEARCH DESIGN AND METHODS
Construction of expression vector for K5. The human K5 cDNA (362 bp)
was ampliﬁed by PCR using a pair of primers containing a 6 histidine tag
(His-tag) at the COOH-terminus of K5. For secretion of K5, a 52-bp linker
encoding the signal peptide was cloned into a pcDNA3.1(). The ampliﬁed K5
cDNA with the His-tag sequence was subcloned into pcDNA3.1() vector at
the BamHI and XbaI sites in frame with the signal peptide sequence. The
resulting pcDNA3.1()-SP-K5–6His-tag expression construct was conﬁrmed
by restriction digestion and DNA sequencing.
Preparation and characterization of PLGA:Chitosan pK5-NPs
Preparation of PLGA:Chitosan pK5-NPs. PLGA:Chitosan nanoparticles
containing the K5 expression plasmid (PLGA:CHN pK5-NPs) were pre-
pared using a previously reported emulsion-diffusion evaporation tech-
nique (24) with some modiﬁcations. Brieﬂy, 15.5 mg PLGA (50:50, 0.17 i.v.;
Birmingham Polymers) was dissolved in 5 ml ethyl acetate. The polyvinyl
acetate solution (1%, wt/vol) was prepared and then chitosan chloride
(Nova Matrix PCL 113, 2.5 mg) was stirred until dissolved. Plasmid solution
(1 ml containing 350 g plasmid) was modiﬁed with 10% (wt/vol) sodium
sulfate and added to the chitosan solution for complexation and DNA
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20
30
kDa 1     2      3    4    5
20
30
kDa 1      2      3    4    5
B
A
C
Control -NP
Control -NP
K5 -NP
K5 -NP
FIG. 1. K5 expression from K5-NP in vitro. ARPE19 cells were grown to 70% conﬂuence in a medium containing 5% FBS. The culture medium
was replaced by a serum-free medium. Control-NP and K5-NP were separately added into the medium to 1 g/ml (plasmid DNA
concentration) and incubated with the cells for 72 h. A: The medium was collected and concentrated. Total protein concentrations in the
media were measured using the Bradford assay. The same amount of total proteins (20 g) was applied for Western blot analysis separately
using an antibody speciﬁc for human K5 and an anti–His-tag antibody. Lane 1, molecular weight markers; lane 2, medium from cells treated
with K5-NP; lane 3, untreated cells; lane 4, treated with control-NP; lane 5, puriﬁed K5 peptide as positive control. B and C: ARPE19 cells
were grown overnight on glass slides, treated with K5-NP and control-NP at 1 g/ml for 72 h, washed, and ﬁxed. The cells were
immunostained with a monoclonal antibody against the His-tag using a 3,3-diaminobenzidine color reaction that shows brown color in cells
with positive immunostaining. B: 100, C: 400. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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DIABETES, VOL. 58, AUGUST 2009 1903condensation and stirred. Both solutions were then combined and emulsi-
ﬁed with a probe sonicator for 4 min. To the emulsion, 30 ml Milli-Q H2O
was added and stirred on a magnetic plate stirrer for 3 h to evaporate the
solvent. The particle suspension was ultracentrifuged and resuspended in
Milli-Q H2O, and the procedure was repeated twice. Upon ﬁnal resuspen-
sion in Milli-Q H2O, the nanoparticle suspension was lyophilized to obtain
dry particles.
Particle size and -potential measurement. The particle size and size
distribution were determined using dynamic light scattering (Brookhaven
Instruments, Holtsville, NY). The same equipment was used to determine the
-potential of the particles.
Estimation of plasmid loading in nanoparticles. For plasmid loading
estimation, the lyophilized product (0.2 mg) was dispersed in 1 ml methylene
chloride to dissolve the polymer, followed by extraction of the plasmid into 2
ml Tris-EDTA buffer. An aliquot of the Tris-EDTA buffer fraction was analyzed
for the absorbance at 260 nm to determine the plasmid content per milligrams
of nanoparticles.
Western blot analysis. For in vitro assay, protein extracts were prepared
from a human Mu ¨ller cell line (MIO-M1) (a generous gift from Drs. Khaw and
Limb [25]) and treated with Control-NP or K5-NP under hypoxia for 48 h. For
in vivo assay, the free-ﬂoating retinas were homogenized in 150 l ice-cold
tissue lysis buffer (50 mmol/l Tris-HCl, pH 7.4, 2 mmol/l MgCl2, 1% NP-40, 10%
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FIG. 2. Inhibitory effect of K5-NP on endothelial cell growth and VEGF overexpression under hypoxia. A: BRCECs grown in media containing 1%
FBS were treated with K5-NP at the concentrations as indicated for 72 h. The viable cells were quantiﬁed using the MTT assay. K5-NP induced
a dose-dependent decrease of cell viability in BRCECs. B: At the same concentrations, K5-NP did not inhibit ARPE19 cell growth. C: ARPE19 cells
were treated separately with 1 g/ml control-NP and K5-NP for 72 h. The culture medium was replaced with a serum-free medium, and the cells
were exposed to hypoxia for 24 h. VEGF secreted into the medium was measured by ELISA using an ELISA kit (R&D Systems, Minneapolis, MN)
and normalized by total protein concentrations in the medium. D: Total RNA was extracted from the treated ARPE19 cells, and VEGF mRNA levels
were quantiﬁed by RT-PCR and normalized by 18S rRNA levels. Values are mean  SD (n  3). , Hypoxia; f, normoxia. E:M u ¨ller cells were
treated separately with 1 g/ml control-NP and K5-NP for 72 h. The culture medium was replaced with a serum-free medium, and the cells were
exposed to hypoxia for 24 h. VEGF and HIF-1 levels were analyzed by immunoblotting and normalized by -actin levels.
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1904 DIABETES, VOL. 58, AUGUST 2009glycerol, 100 mmol/l NaCl) and a protease inhibitor cocktail (1:100 dilution,
Sigma Aldrich, St. Louis, MO) added just before use. The lysates were cleared
by centrifugation at 12,000 g for 20 min at 4°C. The protein concentration of
the lysate was determined using the Bradford assay. The same amount of
proteins (50 g) were resolved by SDS-PAGE in 8% denaturing gels and
transferred onto nitrocellulose membranes. Ponceau S staining (Sigma Al-
drich) was carried out to verify equal protein loading. Immunoblotting and
signal detection by enhanced chemiluminescences were performed as de-
scribed previously by incubating the membranes with the primary antibodies
against rabbit anti-VEGF (1:1,000 in 5% nonfat milk powder/0.1% TBS Tween-
20, Santa Cruz), HIF-1 (1:1,000; BD Transduction Laboratories), goat anti-
ICAM-1 (1:1,000; Santa Cruz), mouse anti–His-tag (1:2,000; Upstate), mouse
anti-TATA box-binding protein (TATA-binding protein [TBP], 1:1,000; Abcam),
or mouse anti–-actin (1:2,000; Abcam) antibodies overnight at 4°C. The signal
intensity was quantiﬁed by densitometry using software (SynGene, Frederick,
MD).
Immunohistochemistry. Immunostaining was performed as described pre-
viously (26). Brieﬂy, the eyes were cross-sectioned vertically through the
center of the cornea and optic nerve, and both halves of the eyeball were
embedded with the center facing down. Serial cryosection (5 m thickness)
was blocked with 10% goat serum in 0.1% Triton X-100 and 3% BSA in PBS.
After PBS washes, the antibody speciﬁc for the His-tag was added and
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FIG. 3. K5 expression in the rat retina after an intravitreal injection of K5-NP. A–D: K5-NP was injected into the vitreous of the right eyes and
control-NP into the contralateral eyes of four OIR rats at P12. K5 expression was examined at P18 by immunohistochemistry in ocular sections
using an anti–His-tag antibody (green). The nuclei were counterstained with DAPI (red). A and C: Representative immunostaining images from
the eyes injected with K5-NP (A) and control-NP (C). B and D: Phase contrast images of the same areas shown in A and C, respectively. Scale bar:
20 m. E: K5-NP and control-NP were separately injected into the vitreous. The retinas were dissected at 1, 2, 3, and 4 weeks after the injection
of K5-NP or control-NP (three rats per time point). The same amount of proteins (100 g) from each retina was loaded for Western blot analysis
using the anti–His-tag antibody. The same membrane was striped and re-blotted with an anti–-actin antibody. No K5 expression was found in the
retinas injected with control-NP, whereas K5 expression was detected in all of the retinas with the K5-NP injection. GCL, ganglion cell layer; INL,
inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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times with PBS and incubated with a ﬂuorescein isothiocyanate conjugated
anti-mouse IgG antibody for 1 h. The slides were then rinsed in cold PBS and
viewed under a ﬂuorescence microscope.
Real-time RT-PCR. The reverse transcription and real-time PCRs (RT-PCR)
were performed as described previously (26). The primers used for human
VEGF (5 CAGAGCGGAGAAAGCATTTG and 3 TGGTTCCCGAAACCCTG
AGG) ampliﬁed a 180-bp fragment of VEGF. The 18S rRNA was ampliﬁed
using primers (5 TGCTGCAGTTAAAAAGCTCGT and 3 GGCCTGCTTTG
AACA CTCTAA) for normalization of the VEGF mRNA levels.
Rat models of OIR and STZ-induced diabetes. All the animal experiments
were performed in compliance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Brown Norway rats (Charles
River Laboratories) were used for the OIR model following an established
protocol (27). OIR rats received an intravitreal injection of K5-NP into the
right eye and the same dose of Control-NP into the left eye at age of P12.
Diabetes was induced and monitored in adult Brown Norway rats by an
intraperitoneal injection of STZ (50 mg/kg in 10 mmol/l of citrate buffer, pH
4.5) as described previously (14,28). Diabetic rats at 2 weeks after the onset of
diabetes received an intravitreal injection of Control-NP and K5-NP in the
treatment group and the same dose of Control-NP in the control group.
Retinal vascular permeability assay. Retinal vascular permeability was
measured using the Evens blue-albumin leakage assay following an estab-
lished protocol (29). Concentrations of Evans blue in the retina were
normalized by total retinal protein concentrations and by Evans blue concen-
trations in the plasma.
Fluorescein retinal angiography and quantifying preretinal vascular
cells. Retinal vasculature was visualized by ﬂuorescein angiography as
described (13,27). The neovascular area was measured in the retina using
SPOT software (Diagnostic Instruments, Sterling Heights, MI). For quantiﬁ-
cation of preretinal vascular cells, eyes were ﬁxed, sectioned, and stained as
described previously (27). The preretinal nuclei were counted, averaged, and
compared using Student’s t test.
Electroretinogram recording. Rats were dark adapted for at least 12 h. The
rats were killed and pupils dilated with topical application of 2.5% phenylephrine
and 1% tropicamide. Electroretinogram (ERG) responses were recorded with a
silver chloride needle electrode placed on the surface of the cornea after 1%
tetracaine topical anesthesia. A reference electrode was positioned at the nasal
fornix and a ground electrode on the foot. The duration of light stimulation was
10 ms. The band pass was set at 0.3–500 Hz. Fourteen responses were recorded
and averaged with ﬂash intervals of 20 s. For quantitative analysis, the B-wave
amplitude was measured between A- and B-wave peaks. The ERG waveforms of
both eyes in the same animal were simultaneously recorded and compared using
the right-to-left eye ratio of B-wave amplitude.
Measurement of nuclear levels of hypoxia-inducible factor-1. Nuclear
and cytosolic fractions were isolated using the Fractionation System Kit
(Biovision, Mountain View, CA). Nuclear and cytosolic protein concentrations
were measured using the Bradford assay. The proteins were blotted with an
antibody speciﬁc for hypoxia-inducible factor-1 (HIF-1; Santa Cruz Biotech-
nology, Santa Cruz, CA) at 1:500 dilution.
RESULTS
Characteristics of K5-NP. Nanoparticle size, polydisper-
sity index, -potential, and plasmid loading were measured
with four different nanoparticle batches, and various pa-
rameters are shown below (mean 	 SD). The nanoparticle
formulation exhibited a mean hydrodynamic diameter of
260 	 30 nm, a polydispersity index of 0.28 	 0.005,
-potential of 8.4 	 2.4 mV, and a plasmid loading of 11 	
1.4 g/mg particles.
K5 expression from K5-NP in cultured cells. ARPE19
cells were transfected with 10 g of K5-NP or Control-NP
for 3 days. The concentrated conditioned serum-free me-
dium from the transfected cells was blotted separately
with the anti-K5 and anti–His-tag antibodies. Both of the
antibodies detected signiﬁcant amounts of K5 with the
expected molecular weight secreted from the cells trans-
fected with K5-NP, but not from the cells transfected with
Control-NP (Fig. 1A).
The K5 expression was also determined by immuno-
cytochemistry using the anti–His-tag antibody. The an-
tibody detected K5 signal in the cells transfected with
K5-NP, but not in the cells transfected with Control-NP
(Fig. 1B and C).
Speciﬁc inhibition of endothelial cell growth and
VEGF overexpression by K5-NP. To determine the
biological effect of K5-NP, primary bovine retinal capillary
endothelial cells (BRCECs) and ARPE19 cells were treated
with K5-NP for 3 days, and viable cells were quantiﬁed
using the MTT assay. As shown in Fig. 2A and B, K5-NP
induced a dose-dependent decrease in viable BRCEC num-
bers, when compared with the untreated cells and the cells
treated with Control-NP (Fig. 2A). In contrast, the same
K5-NP treatment did not result in signiﬁcant reduction of
viable cells in ARPE19 (Fig. 2B), suggesting that the in-
hibitory effect of K5-NP on cell growth is endothelial
cell–speciﬁc.
Our previous studies showed that K5 inhibits angiogen-
esis via downregulation of VEGF expression (30). Here we
evaluated the effect of K5-NP on VEGF expression by
measuring VEGF secretion and VEGF mRNA levels. As
shown by ELISA, ARPE19 cells overexpressed VEGF after
exposure to hypoxia (1% O2). K5-NP treatment signiﬁ-
cantly reduced the VEGF secretion induced by hypoxia, to
a level comparable to that from the cells under normoxia
(Fig. 2C). Similarly, RT-PCR showed that K5-NP signiﬁ-
cantly downregulated the VEGF mRNA expression under
hypoxia, whereas Control-NP did not affect VEGF expres-
sion under the same conditions (Fig. 2D).
The effects of K5-NP were also evaluated in cultured
rMc-1, a cell line derived from rat retinal Mu ¨ller cells (31).
As shown by Western blot analysis, K5-NP attenuated the
overexpression of VEGF and decreased HIF-1 levels in
Mu ¨ller cells cultured under hypoxia (1% O2) (Fig. 2E).
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FIG. 4. Effect of K5-NP on retinal vascular leakage in OIR rats. OIR rats
received an intravitreal injection of 2.2 g( A)o r8 . 8g( B) of K5-NP
into the right eyes and the same dose of control-NP into the left eyes at
P12. Retinal vascular permeability was measured using the Evans
blue-albumin leakage method at P16. The vascular leakage was normal-
ized by total protein concentrations in the retina, averaged within the
group (mean  SD, n  7) and compared with contralateral eyes using
paired Student’s t test. The eyes injected with 8.8 g of K5-NP showed
a signiﬁcantly lower retinal vascular permeability compared with the
contralateral eye (P  0.011) (B).
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1906 DIABETES, VOL. 58, AUGUST 2009Sustained expression of K5 in the retina after an
intravitreal injection of K5-NP. To examine the expres-
sion of K5 from K5-NP in the retina, K5-NP was injected
into the vitreous of the right eye (8.8 g/eye) and the same
amount of Control-NP into the left vitreous of four OIR
rats at age of postnatal day 12 (P12) after exposure to 75%
oxygen. At age P18, the immunohistochemistry was per-
formed on retinal sections using the anti–His-tag antibody.
The immunostaining detected high levels of K5 expression
in the inner retina in the eyes injected with K5-NP, but not
in the contralateral control eyes (Fig. 3A–D).
To determine the duration of the K5 expression after a
single injection of K5-NP, the retinas were dissected and
homogenized at 1, 2, 3, and 4 weeks after an intravitreal
injection of K5-NP in adult rats (three rats per time point)
for Western blot analysis using the anti–His-tag antibody.
K5 was detected with an expected molecular weight in
the retinas injected with K5-NP at all the time points
analyzed (Fig. 3E), but not in the retinas injected with the
Control-NP.
K5-NP reduces retinal vascular leakage in OIR rats.
To evaluate the effect of K5-NP on retinal vascular leakage,
K5-NP was injected intravitreally into the right eye (2.2 or
8.8 g/eye) at age P12 and the same amount of Control-NP
into the contralateral eyes. Retinal vascular leakage was
measured at P16 using the Evans blue-albumin leakage
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FIG. 5. Effect of K5-NP on retinal neovascularization in OIR rats. K5-NP was injected into the vitreous of the right eyes (8.8 g/eye) and the same
amount of control-NP into the contralateral eyes of seven OIR rats at P12. Retinal vasculature was examined using ﬂuorescein angiography at
P18 as described in METHODS. A and C: Representative retinal angiographs from the eyes injected with control-NP; B and D are representative
angiographs from the K5-NP–injected eyes (40 in A and B; 100 in C and D). Scale bar: A and B, 100 m; C and D,4 0m. E: Retinal
neovascularization was quantiﬁed by measuring the neovascular area in the retina and expressed as percent of the total retina area (mean  SD,
n  7). The difference of the neovascular area was compared with the contralateral eyes using paired Student’s t test. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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results showed that the eyes injected with 8.8 g of K5-NP
had signiﬁcantly lower vascular permeability than that in
the contralateral retinas injected with Control-NP (P 

0.011, n 
 7; Fig. 4B). The injection of 2.2 g of K5-NP did
not result in a statistically signiﬁcant decrease of vascular
leakage (P 
 0.0531, n 
 7; Fig. 4A).
K5-NP inhibits ischemia-induced retinal neovascular-
ization. To evaluate the effect of K5-NP on retinal neovas-
cularization, K5-NP was injected intravitreally into the
right eyes (8.8 g/eye) of the OIR rats at P12 and Con-
trol-NP into the left eyes. The retinal vasculature was
visualized and examined by ﬂuorescein retinal angiogra-
phy at P18. Retinal angiographs on retinal ﬂat mounts
showed that the eyes injected with Control-NP developed
severe retinal neovascularization in the OIR rats (Fig. 5A
and C). In contrast, a single K5-NP injection ameliorated
the retinal neovascularization in the same rats by decreas-
ing neovascular areas and nonperfusion areas in the retina
(Fig. 5B and D). The neovascularization was semi-quanti-
ﬁed by measuring the ratio of the neovascular area to the
total retina area, which showed that the eyes injected with
K5-NP have signiﬁcantly decreased retinal neovascular
areas in the OIR rats, compared with those injected with
Control-NP (Fig. 5E).
The effect of K5-NP on preretinal neovascularization
was also quantiﬁed by counting vascular cells growing into
the vitreous space (preretinal vascular cells) on eight
noncontinuous cross-sections from each eye following an
established method (27). The result showed that the eyes
injected with K5-NP have signiﬁcantly fewer preretinal
neovascular cells, compared with the contralateral eyes
injected with Control-NP (Fig. 6).
K5-NP reduces retinal vascular leakage and blocks
expression of VEGF and ICAM-1 in STZ-induced
diabetic rats. To determine the effect of K5-NP on retinal
inﬂammation, K5-NP was injected intravitreally into STZ-
induced diabetic rats, with the same dose of Control-NP as
vehicle control. As VEGF and ICAM-1 are both known to
play important roles in the retinal inﬂammation and blood-
retinal barrier breakdown in diabetes, we measured retinal
levels of ICAM-1 and VEGF from nondiabetic rats, STZ-
induced diabetic rats, and diabetic rats treated with Con-
trol-NP and K5-NP using Western blot analysis. Four
weeks after the injection, the retinas from rats injected
with K5-NP showed decreased retinal VEGF and ICAM-1
levels by more than 50%, compared with that in the retina
injected with Control-NP and to that in untreated diabetic
rats (Fig. 7A). Consistently, leukostasis assay showed that
K5-NP also decreased adherent leukocytes in the retinal
vasculature of diabetic rats (supplementary Fig. 1, avail-
able in an online appendix at http://diabetes.diabetes
journals.org/cgi/content/full/db08-1327/DC1). Retinal
vascular permeability in the retinas of nondiabetic and
STZ-induced diabetic rats, and diabetic rats treated with
Control-NP and K5-NP, was measured using the Evans
blue-albumin leakage method. As shown by retinal
vascular permeability assay, K5-NP reduced retinal vas-
cular leakage by 30% in STZ-induced diabetic rats, 4
weeks after the injection of K5-NP (P  0.001, Fig. 7B),
suggesting that the effect of K5-NP on retinal vascular
leakage lasted for at least 4 weeks after a single
injection. In contrast, Control-NP injection did not
result in any signiﬁcant difference in retinal levels of
VEGF and ICAM-1 or retinal vascular leakage in the
diabetic rats.
Lack of detectable toxicities to the structure and
function of the retina. Possible toxicities of K5-NP
were evaluated structurally by histological analysis. The
eyes from rats with K5-NP injection and those with
Control-NP injection were sectioned, stained, and exam-
ined under light microscope at 1, 2, and 4 weeks after
the injection. No difference was observed in number of
retinal nuclear layers or thickness of the retina among
the rats injected with K5-NP and the control (Fig. 8A–F).
We also measured the retinal thickness at the same six
retinal locations in each eye as described in supplemen-
tary METHODS. There is no signiﬁcant difference in retinal
thickness in the rats treated with K5-NP and controls
(supplementary Fig. 2, available in the online appendix).
Similarly, K5-NP did not increase apoptotic cells in
the retina (supplementary Fig. 3, available in the online
appendix).
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FIG. 6. Effect of K5-NP on preretinal neovascularization in OIR rats.
K5-NP was injected intravitreally into the right eyes and control-NP into
the left eyes of six OIR rats at P12. The eyes were ﬁxed, sectioned, and
stained with hematoxylin and eosin at P18. A and B: Representative
sections from the eyes injected with control-NP (A) and from that with
K5-NP (B) injection. Scale bar: 40 m. C: Preretinal vascular cells were
counted in eight noncontinuous sections per eye and averaged as de-
scribed in RESEARCH DESIGN AND METHODS. The average numbers of preretinal
vascular cells (mean  SD, n  6) were compared with the eyes injected
with K5-NP and those with Control-NP using paired Student’s t test. (A
high-quality digital representation of this ﬁgure is available in the online
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were evaluated by ERG recording in normal and diabetic
rats. As shown in Fig. 8, the amplitudes of A- or B-waves
were not signiﬁcantly different among the Control-NP or
K5-NP treated rats and untreated rats. STZ-induced dia-
betic rats showed ERG responses similar to the nondia-
betic rats (Fig. 8G and H).
K5-NP inhibits the activation of HIF-1. To investigate
the mechanism responsible for the anti-angiogenic activity
of K5-NP, we have measured the effect of K5-NP on HIF-1
activation, since HIF-1 is the key transcription factor
activating VEGF and is known to play a key role in retinal
neovascularization (7). HIF-1 nuclear translocation is a
critical step in the activation of HIF-1, and thus, we
measured cytosolic and nuclear levels of HIF-1 in the
human Mu ¨ller cell line treated with K5-NP under hypoxia.
As shown by Western blot analysis of isolated nuclear
proteins, exposure of the cells to hypoxia (1% oxygen)
FIG. 7. Effect of K5-NP on retinal vascular leakage and expression of VEGF and ICAM-1 in diabetic rats. STZ-induced diabetic rats at 2 weeks after
the onset of diabetes received an intravitreal injection of 5 g/eye of K5-NP in the treatment group and the same dose of control-NP in the control
group. A: Four weeks after the injection, retinal levels of ICAM-1 and VEGF from nondiabetic control, untreated diabetic rats, and diabetic rats
treated with control-NP and K5-NP were determined using immunoblotting. The same membrane was stripped and re-blotted with the anti–His-tag
and anti–-actin antibodies. Retinal levels of VEGF and ICAM-1 in diabetic rats treated with control-NP and K5-NP were quantiﬁed by
densitometry and expressed as percent of that in nondiabetic rat retinas (mean  SD, n  3). B: Retinal vascular permeability in the retina of
nondiabetic rats, untreated diabetic rats, and diabetic rats treated with control-NP and K5-NP was measured using the Evans blue-albumin
leakage method at 4 weeks after the injection of control-NP or K5-NP, normalized by the total protein concentration in the retina and the Evans
blue concentration in the blood and expressed as nanogram dye per milligram of retinal proteins (mean  SD, n  8).
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DIABETES, VOL. 58, AUGUST 2009 1909increased HIF-1 levels in the nuclei (Fig. 9A). K5-NP, but
not Control-NP, completely blocked the increase of nu-
clear HIF-1 levels under hypoxia (Fig. 9A).
Similarly, nuclear translocation of HIF-1 was also
determined in the retina of the OIR rats by immunostain-
ing of HIF-1. OIR rats showed high levels of HIF-1 in the
nuclei in the inner retina injected with Control-NP (Fig.
9B–D). In the contralateral eyes injected with K5-NP, the
HIF-1 signal in the nuclei of retinal cells was apparently
decreased (Fig. 9E–G), suggesting that K5-NP inhibited
HIF-1 nuclear translocation.
DISCUSSION
Retinal vascular leakage, the direct cause of diabetic
macular edema, and retinal neovascularization are the
major causes of vision loss in diabetic patients (1).
Long-term suppression of retinal vascular leakage and
pathologic retinal neovascularization are the goals for
the treatment of diabetic retinopathy. Although previ-
ous studies showed that peptide angiogenic factors such
as K5, angiostatin, and so forth effectively reduce vas-
cular leakage and inhibit retinal neovascularization in
rat models (14,32), the difﬁculty in achieving sustained
ocular delivery of the peptides represents a major
hurdle for their therapeutic applications. The present
study reports the ﬁrst approach to combine an endoge-
nous angiogenic inhibitor with nanotechnology in the
treatment of diabetic retinopathy. Our results showed
that an intravitreal injection of K5-NP mediated high-
level and sustained K5 expression in the retina and
resulted in sustained reductions of retinal vascular
leakage in STZ-induced diabetic and OIR models. Fur-
ther, K5-NP effectively blocked ischemia-induced retinal
neovascularization. This study also identiﬁed a novel
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1910 DIABETES, VOL. 58, AUGUST 2009anti-inﬂammatory effect of K5 in the retina of diabetic
rats. Moreover, the K5-NP injection did not result in any
detectable toxicity to retinal structure and function.
This study revealed therapeutic potential of nanopar-
ticle-mediated gene delivery of angiogenic inhibitors in
the treatment of diabetic retinopathy.
Nanoparticles formulated using PLGA polymers are
recently being investigated as a new gene delivery system
because of their sustained release characteristics, biocom-
patibility, biodegradability, and ability to protect DNA
from degradation in lysosomes (33,34). Our immunoblot-
ting and double immunostaining results showed that
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cultured cells and in the inner retina, suggesting that
K5-NP is efﬁciently internalized and released into the
cytoplasmic compartment rather than being retained in
the degradative lysosomal compartment. Moreover, the
expressed K5 is secreted into the extracellular space and
has biological activity of speciﬁcally inhibiting endothelial
cell growth and VEGF overexpression under hypoxia and
in the retina of STZ-induced diabetes.
Cytotoxicity is a potential concern in some nanopar-
ticle-mediated gene deliveries. We have determined poten-
tial cytotoxicities of K5-NP in cultured ARP19 cells and in
the retina. In ARPE19 cells treated with K5-NP, no signif-
icant reduction in cell viability was observed. In contrast,
the same concentrations of K5-NP signiﬁcantly inhibited
endothelial cell growth, suggesting an endothelial cell-
speciﬁc inhibitory effect of K5-NP. After an intravitreal
injection of K5-NP, no signiﬁcant alterations were ob-
served in the retinal histology at any of the time points
analyzed. Moreover, analyses of the ERG response, retinal
thickness, and cell death in the retina suggest that K5-NP
does not have any detectable side effects on retinal
structure and functions. These data suggest that K5-NP
has no severe toxicities at the dose used.
Our previous studies demonstrated that the anti-angio-
genic activity of K5 is through downregulating the expres-
sion of VEGF (30). As VEGF is a major permeability and
angiogenic factor, downregulation of VEGF expression is
believed to be responsible for the effects of K5 on vascular
leakage and retinal neovascularization (14,15). To conﬁrm
whether the expressed K5 from nanoparticles plays a role
in blocking the VEGF overexpression under hypoxia, we
measured VEGF expression in retinal pigment epithelium
cells and Mu ¨ller cells. Exposure of the cells to hypoxia
increased the VEGF expression. The overexpression of
VEGF under hypoxia can be effectively blocked by K5-NP,
suggesting that the mechanism underlying the vascular
activities of K5-NP is identical to that of the K5 peptide.
The OIR model is commonly used for studies of prolif-
erative diabetic retinopathy (35–37). Although it is not a
diabetic model, the pathology in the retina in this model is
similar to that in diabetic retinopathy in humans (27).
Moreover, VEGF overexpression has been shown to be the
key pathogenic factor for retinal vascular leakage and
neovascularization in this model, a pathogenic mechanism
similar to that in diabetic retinopathy (8,38). Our results
showed that K5-NP reduced retinal vascular permeability
in a dose-dependent manner, demonstrating a beneﬁcial
effect on vascular leakage induced by hypoxia.
To evaluate the effect of K5-NP on retinal neovascular-
ization in the OIR model, we used ﬂuorescein angiography
on ﬂat-mounted retinas. The results showed that a single
injection of K5-NP signiﬁcantly reduced retinal neovascu-
lar area and nonperfusion area that have been shown to
correlate with the severity of diabetic retinopathy (27,35).
Because preretinal neovascularization (i.e., neovascula-
ture growing into the vitreous space) is a characteristic of
proliferate diabetic retinopathy, we have also evaluated
the effect of K5-NP on preretinal neovascular events. The
results showed that K5-NP signiﬁcantly reduced preretinal
neovascular cells, compared with the contralateral eyes
injected with Control-NP. These results demonstrate that
K5-NP attenuates ischemia-induced retinal neovasculariza-
tion. A limitation of the OIR model, however, is that both
the vascular leakage and retinal neovascularization are
transient, with peaks at P16 and P18, respectively (27,28).
Sustained expression is a goal of gene delivery. In the
entire experimental period (4 weeks), K5-NP mediated
efﬁcient expression of K5 in the retina. To evaluate the
sustained effects of K5, we have used the STZ-diabetic rat
model, a commonly used type 1 diabetic model. As STZ-
induced diabetic rats are known to develop vascular
leakage and retinal inﬂammation but not neovasculariza-
tion, we measured the effect of K5-NP on retinal vascular
leakage and inﬂammation in the STZ-induced diabetic
model. Our results showed that K5-NP reduced retinal
vascular leakage for at least 4 weeks after a single injec-
tion in diabetic rats. Further, K5-NP attenuated the over-
expression of VEGF and ICAM-1, two major inﬂammatory
factors (3,39). Further, K5-NP also decreased leukostasis
in the retina of the diabetic rats. These results indicate that
K5-NP has a novel anti-inﬂammatory activity.
In conclusion, the present study demonstrates that
PLGA nanoparticles can be used for gene delivery of
angiogenic inhibitors into the retina without toxicity. The
nanoparticle-mediated nonviral gene delivery of angio-
genic inhibitors has therapeutic potential for the treatment
of diabetic macular edema and retinal neovascularization
associated with several ocular disorders such as diabetic
retinopathy.
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